Upper Gastrointestinal Research, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Clin Gastroenterol Hepatol. 2012 Oct;10(10):1136-1142.e3. doi: 10.1016/j.cgh.2012.06.023. Epub 2012 Jul 16.
BACKGROUND & AIMS: Patients with celiac disease have been reported to be at increased risk for pancreatitis and pancreatic insufficiency, but the risk might have been overestimated because of patient selection and limited numbers of patients for analysis. Furthermore, no distinction has been made between patients with gallstone-related and non-gallstone-related pancreatitis. We performed a nationwide study to determine the risk for any pancreatitis or subtype of pancreatitis among patients with biopsy-verified celiac disease.
We analyzed data from patients in Sweden with celiac disease (n = 28,908) who were identified on the basis of small intestinal biopsy records from 28 pathology departments (those with villous atrophy, Marsh 3). Biopsies were performed from 1969 to 2008, and biopsy report data were collected from 2006 to 2008. Patients with pancreatitis were identified on the basis of diagnostic codes in the Swedish Patient Register and records of pancreatic enzyme use in the Swedish Prescribed Drug Register. Data were matched with those from 143,746 individuals in the general population; Cox regression was used to estimate hazard ratios (HRs) for pancreatitis.
We identified 406 patients with celiac disease who were later diagnosed with pancreatitis (and 143 with expected pancreatitis) (HR, 2.85; 95% confidence interval [CI], 2.53-3.21). The absolute risk of any pancreatitis among patients with celiac disease was 126/100,000 person-years, with an excess risk of 81/100,000 person-years. The HR for gallstone-related acute pancreatitis was 1.59 (95% CI, 1.06-2.40), for non-gallstone-related acute pancreatitis HR was 1.86 (95% CI, 1.52-2.26), for chronic pancreatitis HR was 3.33 (95% CI, 2.33-4.76), and for supplementation with pancreatic enzymes HR was 5.34 (95% CI, 2.99-9.53). The risk of any pancreatitis within 5 years of diagnosis was 2.76 (95% CI, 2.36-3.22).
Based on an analysis of medical records from Sweden, patients with celiac disease have an almost 3-fold increase in risk of developing pancreatitis, compared with the general population.
已有报道称,乳糜泻患者发生胰腺炎和胰腺功能不全的风险增加,但由于患者选择和分析的患者人数有限,这种风险可能被高估了。此外,尚未对胆石性和非胆石性胰腺炎患者进行区分。我们进行了一项全国性研究,以确定经活检证实的乳糜泻患者发生任何类型胰腺炎或特定类型胰腺炎的风险。
我们分析了瑞典 28908 例乳糜泻患者的数据,这些患者是根据 28 个病理部门的小肠活检记录(绒毛萎缩,Marsh 3 级)确定的。活检于 1969 年至 2008 年进行,活检报告数据于 2006 年至 2008 年收集。胰腺炎患者是根据瑞典患者登记处的诊断代码和瑞典处方药物登记处的胰腺酶使用记录确定的。数据与普通人群中的 143746 人进行了匹配;使用 Cox 回归估计胰腺炎的风险比(HR)。
我们发现 406 例乳糜泻患者随后被诊断为胰腺炎(和 143 例预期为胰腺炎)(HR,2.85;95%置信区间[CI],2.53-3.21)。乳糜泻患者的任何类型胰腺炎的绝对风险为 126/100000 人年,超额风险为 81/100000 人年。胆石性急性胰腺炎的 HR 为 1.59(95%CI,1.06-2.40),非胆石性急性胰腺炎的 HR 为 1.86(95%CI,1.52-2.26),慢性胰腺炎的 HR 为 3.33(95%CI,2.33-4.76),胰腺酶补充治疗的 HR 为 5.34(95%CI,2.99-9.53)。诊断后 5 年内任何类型胰腺炎的风险为 2.76(95%CI,2.36-3.22)。
基于对瑞典病历的分析,与普通人群相比,乳糜泻患者发生胰腺炎的风险增加近 3 倍。